
About 10X Genomics
10X Genomics is a publicly listed company based in Pleasanton (United States) founded in 2012. Instrument systems for genomic research and sequencing libraries are developed. 10X Genomics has raised $199.9 million across 7 funding rounds from investors including Fidelity Investments, SVB and SoftBank Group. The company has 1,310 employees. 10X Genomics has completed 7 acquisitions, including CARTANA, Epinomics and Proteintech Group. Its website 10xgenomics.com draws about 251 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its competitors include Mission Bio, Element Biosciences and Cellares; 3 of its 3 listed competitors have raised funding.
Company details
10X Genomics was founded in 2012 and is headquartered in Pleasanton, United States. Instrument systems for genomic research are developed, including the Chromium platform with reagents and consumables for preparing sequencing libraries compatible with Illumina systems. Software for sequence analysis is provided, along with services such as whole-genome sequencing and exome sequencing. Operations focus on partitioning cells or DNA fragments via GemCode technology to enable barcoded libraries.
- Headquarters Pleasanton, United States
- Employees 1,310
- Stage Public
- SectorsHealthcare
- Website 10xgenomics.com
- Social LinkedIn X Facebook YouTube
- Legal Name 10X Genomics, Inc.
- Annual Revenue$642.82 M (USD)5.25as on Dec 31, 2025
- Net Profit-$43.54 M (USD)76.16as on Dec 31, 2025
- EBITDA-$56.38 M (USD)62.03as on Dec 31, 2025
- Total Equity Funding$199.9M (USD)
in 7 rounds
- Latest Funding Round$85M (USD), Series D
Jan 2019
- InvestorsFidelity Investments
& 9 more
- Employee Count1,310
- Investments & AcquisitionsCARTANA
& 6 more
Apps and channels of 10X Genomics
its YouTube channel 10x Genomics has 6.98K subscribers and 30 videos.
Videos from 10X Genomics
The most watched videos on 10X Genomics's YouTube channel, 10x Genomics (6.98K subscribers). Click a video to play it here.
More on 10x Genomics.
Funding Insights of 10X Genomics
10X Genomics has successfully raised a total of $199.9M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $85 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $199.9M
- Total Rounds 7
- Last Round Series D — $85M
- First Round $3M
(Nov 2012)
- Investors Count 10
All 7 funding rounds of 10X Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | $85M | Series D | – | Meritech, Wells Fargo | |
| Jan 2019 | $161,163 | Grant | – | – | |
| Apr 2018 | $75M | Debt – Venture | – | – | |
| Mar 2016 | $55M | Series C | – | Fidelity Investments | |
| Mar 2015 | $55.5M | Series B | – | – | |
| May 2013 | $1.4M | Series A | – | – | – |
| Nov 2012 | $3M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in 10X Genomics
10X Genomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, SVB and SoftBank Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward US-based companies. | meritechcapital.com | Palo Alto, United States | ||
Venture capital is invested in multiple sectors by Paladin Capital. | paladincapgroup.com | Washington, Dc, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Diverse financial services and online banking are provided to clients. | 1852 | wellsfargo.com | San Francisco, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Investments are directed toward multiple sectors via fund of funds. | 1981 | group.softbank | Minato City, Japan | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for 10X Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of 10X Genomics
339 people are tracked at 10X Genomics (80 in leadership, 6 in board & advisors, 253 in team); the tracked headcount is 1,310.
| Name | Role | Group |
|---|---|---|
Shawn Phillips | Leadership | |
Adam Taich | Chief Financial Officer | Leadership |
Estevan Avila | Vice President Business Solutions And Programs | Leadership |
Rich Ruiz | Senior Director, Global Supply Chain | Leadership |
Di Mo | Vice President Of Sales - APAC | Leadership |
Angelique H. | Sr. Director, Corporate Marketing & AMER Regional Marketing | Leadership |
Ben Hindson | Chief Scientific Officer, President & Co-Founder | Leadership |
Anne Readel | Director, Transactions Counsel | Leadership |
Richard Gardner | VP Corporate Controller | Leadership |
Anita Vanhall | Vp, Tax & Treasury | Leadership |
Mennah Moustafa | Chief Commercial Officer (cco) | Leadership |
Randy Wu | Vice President Of Intellectual Property And Litigation | Leadership |
Rajiv Bharadwaj | Vice President, R&d | Leadership |
Richard Lee | Director Of Sales | Leadership |
Deepthi Vijayraghavan | Commercial Chief Of Staff | Leadership |
Robert Walters | Sales Director Europe, Latin America, Middle East And Africa At 10x Genomics | Leadership |
Jaclyn Z. Damico | Director Of Sales, East | Leadership |
Venkataraghavan Gandur | Sr Director Of Data Platform | Leadership |
Michael Schnall-Levin | Chief Technology Officer, Founding Scientist | Leadership |
Brian Olson | Director, Manufacturing | Leadership |
319 more people are available in the full profile.
Complete people profiles for 10X Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of 10X Genomics
10X Genomics is a publicly listed company on the NASDAQ with ticker symbol TXG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Sep 2019
- Listed onNASDAQ: TXG
- Listed entity10x Genomics, Inc.
- Exchange sectorHealth technology
- ISINUS88025U1097
- Share price$71.79 (-4.52% on the day) · 2026-10-13
- Market capitalisation$9.35B
- EPS (diluted, trailing year)$-0.59
- Volume (last session)4,041,152
Financials of 10X Genomics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $642.8M | -$43.5M | -$56.4M |
| 2024 | $610.8M | -$182.6M | -$148.5M |
| 2023 | $618.7M | -$255.1M | -$158.2M |
| 2022 | $516.4M | -$166.0M | -$130.7M |
| 2021 | $490.5M | -$58.2M | -$24.7M |
Detailed financial statements for 10X Genomics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 10X Genomics
10X Genomics has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include CARTANA, Epinomics and Proteintech Group.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Supplies high-quality antibodies, immunoassays, and cytokines for scientific applications globally. | ptglab.com | Chicago, United States | 2002 | Jun 2026 | •••• | |
Scale Biosciences is a company developing single-cell library preparation kits for genomic, epigenomic, and transcriptomic analysis. | scale.bio | San Diego, United States | 2020 | Aug 2025 | •••• | |
Antigens, peptides, and tetramers for research are supplied online. | tetramer-shop.com | Kongens Lyngby, Denmark | 2018 | Feb 2021 | •••• | |
Fluorescent in situ RNA sequencing technology | readcoor.com | Cambridge, United States | 2016 | Oct 2020 | $350M | |
Provider of gene expression mapping technology in brain tissue | cartana.se | Solna, Sweden | 2017 | Aug 2020 | $41.2M | |
Tools for gene expression visualization in tissue samples are provided. | spatialtranscriptomics.com | Solna, Sweden | 2013 | Dec 2018 | •••• | |
Epigenomics research and development services for DNA sequencing are provided. | epinomics.co | San Francisco, United States | 2013 | Aug 2018 | •••• |
Complete acquisition details for 10X Genomics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of 10X Genomics
11 dated milestones of 10X Genomics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded 10X Genomics is founded.
- Funding First funding round of $3.0M.
- Acquisition Acquires Epinomics.
- Acquisition Acquires Spatial Transcriptomics.
- Funding Latest funding round, Series D, of $85.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires CARTANA.
- Acquisition Acquires ReadCoor.
- Acquisition Acquires Tetramer Store.
- Acquisition Acquires Scale Biosciences.
- Acquisition Acquires Proteintech Group.
Competitors of 10X Genomics
10X Genomics has 3 listed competitors in our database, 3 of them funded. They include Mission Bio, Element Biosciences and Cellares.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| elementbiosciences.com | 2017 | San Diego, United States | $678.3M | Benchtop DNA sequencers are developed for research and diagnostic uses. | ||
| cellares.com | 2019 | San Francisco, United States | $355M | Medical devices for cell-based therapy manufacturing are produced. |
Detailed competitors of 10X Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of 10X Genomics
The website of 10X Genomics (10xgenomics.com) receives about 251.3K visits a month.
- Monthly visits251.3K
▲ 22.4% vs previous month
Websites whose visitors overlap most with 10X Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biorxiv.org | 100% | 3M | #19,954 | View details | |
satijalab.org | satijalab.org | 98% | #345,259 | – | |
| cell.com | 97% | 5M | #14,619 | View details | |
| biostars.org | 95% | #154,376 | View details | ||
| bioconductor.org | 93% | #143,754 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for 10X Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as 10X Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about 10X Genomics
Complete news archive for 10X Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 10X Genomics
10X Genomics was founded in 2012.
10X Genomics is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.
10X Genomics is a funded company, having raised a total of $199.9M across 7 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Nov 2012.
10X Genomics has 1,310 employees.
Annual revenue of 10X Genomics is $642.82M as on Dec 31, 2025.
10X Genomics was founded in 2012 and is headquartered in Pleasanton, United States. Instrument systems for genomic research are developed, including the Chromium platform with reagents and consumables for preparing sequencing libraries compatible with Illumina systems. Software for sequence analysis is provided, along with services such as whole-genome sequencing and exome sequencing. Operations focus on partitioning cells or DNA fragments via GemCode technology to enable barcoded libraries.
10X Genomics's top competitors include Mission Bio, Element Biosciences and Cellares.
Yes, 10X Genomics is publicly traded on NASDAQ under the ticker symbol TXG.
10X Genomics has made 7 acquisitions, including CARTANA, Epinomics, and Proteintech Group.
10X Genomics has 10 investors. Key investors include Fidelity Investments, SVB, SoftBank Group, Wells Fargo, and European Union.
The website of 10X Genomics receives about 251 thousand visits a month.
